• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Luna Innovations Incorporated

    10/15/24 2:51:26 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email
    SC 13G 1 luna.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information statement pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.) Luna Innovations Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 550351100 (CUSIP Number) Date of Event Which Requires Filing of this Statement: September 30, 2024 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 550351100 13G 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Royce & Associates, LP 52-2343049 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 2,797,038 6 SHARED VOTING POWER 7 SOLE DISPOSITIVE POWER 2,797,038 8 SHARED DISPOSITIVE POWER 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,797,038 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.24% 12 TYPE OF REPORTING PERSON IA CUSIP No. 550351100 13G Item 1(a) Name of Issuer: Luna Innovations Incorporated Item 1(b) Address of Issuer's Principal Executive Offices: 301 First Street SW Suite 200 Roanoke, VA 24011 Item 2(a) Name of Persons Filing: Royce & Associates, LP Item 2(b) Address of Principal Business Office, or, if None, Residence: 745 Fifth Avenue, New York, NY 10151 Item 2(c) Citizenship: New York Corporation Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 550351100 Item 3 If this statement is filed pursuant to rules 13d-1(b), or 13d- 2(b), check whether the person filing is a: (a) [ ] Broker or Dealer registered under Section 15 of the Act (b) [ ] Bank as defined in Section 3(a)(6) of the Act (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (d) [ ] Investment Company registered under Section 8 of the Investment Company Act (e) [X] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 (f) [ ] Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund (g) [ ] Parent Holding Company, in accordance with Rule 13d-1 (b)(ii)(G) (h) [ ] Group CUSIP No. 550351100 13G Item 4 Ownership The securities reported herein are beneficially owned by one or more registered investment companies or other managed accounts that are investment management clients of Royce & Associates, LP ("RALP"), an indirect majority owned subsidiary of Franklin Resources, Inc.("FRI"). When an investment management contract (including a sub advisory agreement) delegates to RALP investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, FRI treats RALP as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies otherwise. Accordingly, RALP reports on Schedule 13G that it has sole investment discretion and voting authority over the securities covered by any such investment management agreement, unless otherwise noted in this Item 4. As a result, for purposes of Rule 13d 3 under the Act, RALP may be deemed to be the beneficial owner of the securities reported in this Schedule 13G. Beneficial ownership by investment management subsidiaries and other affiliates of FRI is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34 39538 (January 12, 1998) relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by RALP are exercised independently from FRI (RALP's parent holding company) and from all other investment management subsidiaries of FRI (FRI, its affiliates and investment management subsidiaries other than RALP are, collectively, "FRI affiliates"). Furthermore, internal policies and procedures of RALP and FRI affiliates establish informational barriers that prevent the flow between RALP and the FRI affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, RALP and the FRI affiliates report the securities over which they hold investment and voting power separately from each other for purposes of Section 13 of the Act. Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI. However, because RALP exercises voting and investment powers on behalf of its investment management clients independently of FRI affiliates, beneficial ownership of the securities reported by RALP is not attributed to the Principal Shareholders. RALP disclaims any pecuniary interest in any of the securities reported in this Schedule 13G. In addition, the filing of this Schedule 13G on behalf of RALP should not be construed as an admission that it is, and it disclaims that it is, the beneficial owner, as defined in Rule 13d 3, of any of such securities. Furthermore, RALP believes that it is not a "group" with FRI affiliates, the Principal Shareholders, or their respective affiliates within the meaning of Rule 13d 5 under the Act and that none of them is otherwise required to attribute to any other the beneficial ownership of the securities held by such person or by any persons or entities for whom or for which RALP or the FRI affiliates provide investment management services. (a) Amount Beneficially Owned: 2,797,038 (b) Percent of Class: 8.24% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 2,797,038 (ii) shared power to vote or to direct the vote __________ (iii) sole power to dispose or to direct the disposition of 2,797,038 (iv) shared power to dispose or to direct the disposition of __________ Item 5 Ownership of Five Percent or Less of a Class. [ ] Item 6 Ownership of More than Five Percent on Behalf of Another Person. NONE Item 7 Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company. NOT APPLICABLE Item 8 Identification and Classification of Members of the Group. NOT APPLICABLE Item 9 Notice of Dissolution of Group. NOT APPLICABLE CUSIP No. 550351100 13G Item 10 Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to it is true, complete and correct. Date: October 15, 2024 By: Daniel A. O'Byrne Vice President
    Get the next $LUNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market. "Luna star

      1/27/25 10:24:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Stock to Be Suspended from Nasdaq Listing

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, due to the Company's inability to meet the March 27, 2025 deadline to file its previously disclosed delinquent filings with the Securities and Exchange Commission to regain compliance, the trading in its securities will be suspended tomorrow, January 7, 2025, and subsequently delisted from The Nasdaq Stock Market LLC ("Nasdaq"). Following the suspension, the Company expects its shares to be eligible to trade on the over-the-counter ("OTC") market, specifically the OTC Expert Market. The suspension/delisting of the Company's stock from Nasdaq does not

      1/6/25 8:30:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Financials

    Live finance-specific insights

    See more
    • Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

      3/12/24 4:20:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

      Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

      12/21/23 9:34:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Acquires Silixa

      Strengthens Portfolio of Distributed Fiber Optic Sensing Solutions Adds Significant New Growth Markets and Applications and Further Expands Global Footprint Conference Call Scheduled for Today, December 21st, at 11:00 AM ET Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the strategic acquisition of Silixa, a UK-based leader in distributed fiber optic sensing solutions. The acquisition further propels Luna's position in the fiber optic sensing market, adding capabilities in distributed acoustic sensing (DAS), distributed temperature sensing (DTS) and distributed strain sensing (DSS) that offer enhanced performance

      12/21/23 9:32:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    SEC Filings

    See more
    • Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/27/25 10:26:44 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

      SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/14/25 1:56:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/6/25 8:30:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Resignation of Pamela Coe

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

      12/27/24 4:40:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

      Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

      10/16/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Luna Innovations with a new price target

      Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

      7/28/23 7:35:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Needham initiated coverage on Luna Innovations with a new price target

      Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

      5/22/23 7:57:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations downgraded by Northland Capital with a new price target

      Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

      3/15/23 8:52:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 12:32:28 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 8:39:20 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/12/24 4:02:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:44:17 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:43:48 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      12/26/24 5:52:51 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care